Alfavir 25 mg (Tablet)

Unit Price: ৳ 90.00 (1 x 10: ৳ 900.00)

Strip Price: ৳ 900.00

Medicine Details

Category	Details
Generic	Tenofovir alafenamide
Company	Incepta pharmaceuticals ltd

Treatment of chronic hepatitis B virus infection in adults with compensated liver disease

Alfavir is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor
Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2’-deoxyadenosine monophosphate analog)
Intracellular tenofovir is subsequently phosphorylated by cellular kinases to the pharmacologically active metabolite tenofovir diphosphate

Recommended dosage of Tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food
No dosage adjustment of Tenofovir alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 ml per minute
Tenofovir alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment
Safety and effectiveness of Tenofovir alafenamide in pediatric patients less than 18 years of age have not been established
No clinically significant differences in safety or efficacy have been observed between elderly subjects and subjects between 18 and less than 65 years of age

Alfavir is a substrate of P-glycoprotein (P-gp) and BCRP
Coadministration of Alfavir with other drugs that inhibit P-gp and BCRP may increase the absorption & plasma concentration of Alfavir
Coadministration of Alfavir with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and other renally eliminated drugs

The prevalence of birth defects in live births was 4.2% (95% CI: 2.6% to 6.3%) and 3.0% (95% CI: 0.8% to 7.5%) following first and second/third trimester exposure, respectively, to TAF-containing regimens
It is not known whether Tenofovir alafenamide & its metabolites are present in human breast milk, affect human milk production or have effects on the breastfed infant

Discontinuation of anti-hepatitis B therapy, including Alfavir may result in severe acute exacerbations of hepatitis B
Alfavir alone is not recommended for the treatment of HIV-1 infection
Patients taking tenofovir prodrugs who have impaired renal function and those taking nephrotoxic agents, including non-steroidal anti-inflammatory drugs, are at increased risk of developing renal-related adverse reactions
Lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported with the use of nucleoside analogs including tenofovir disoproxil fumarate (TDF)

Alfavir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%